Valeant Announces Successful Results from PIII Onychomycosis Study of Efinaconazole

December 19, 2011
Valeant Pharmaceuticals International of Canada announced on December 16 successful results from two large international PIII studies of efinaconazole (IDP-108/KP-103), a treatment for onychomycosis of the toenail discovered by Kaken Pharmaceutical. In both studies, the drug was found to be...read more